ILYM21090 / MB106-CD20-001 / Reagan
Basic Study Information
Purpose:
Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed
or Refractory B-Cell NHL or CLL
Location: University of Rochester Medical Center
Lead Researcher (Principal Investigator)
Lead Researcher:
Patrick Reagan
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search